肿瘤细胞治疗研究
英文原题：Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting.
本通讯重点介绍了 2025 ASH 年会上报告的免疫性血小板减少症 (ITP) 新兴免疫靶向疗法。
这封来信概述了2025年ASH年会上报告的免疫性血小板减少症（ITP）新兴免疫靶向疗法。我们总结了关键数据，包括ianalumab的III期VAYHIT2试验，以及靶向BAFF-R、CD38、CD19和PI3K的新型早期药物与细胞疗法（CD19/BCMA CAR-T）；这些研究为未来ITP管理提供了重要生物学见解和产生假设的线索。
This letter highlights emerging immune-targeted therapies for immune thrombocytopenia (ITP) presented at the 2025 ASH Annual Meeting. We summarize pivotal data, including the Phase III VAYHIT2 trial of Ianalumab, alongside novel early-phase agents targeting BAFF-R, CD38, CD19, PI3K, and cellular therapies (CD19/BCMA CAR-T), which provide crucial biological insights and hypothesis-generating signals for future ITP management.
MEMBER ACCOUNT
登录成功会直接打开下一页。
